Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cell preparation capable of treating allergic rhinitis

A technology for allergic rhinitis and cell preparation, applied in allergic diseases, animal cells, vertebrate cells, etc., can solve problems such as affecting patients' study and work, and obvious general discomfort.

Inactive Publication Date: 2020-01-31
TSINGHUA UNIV
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although allergic rhinitis is not fatal, the patient's nose and general discomfort are obvious, which affects the patient's study and work.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cell preparation capable of treating allergic rhinitis
  • Cell preparation capable of treating allergic rhinitis
  • Cell preparation capable of treating allergic rhinitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1, Preparation of Umbilical Cord Wharton Section Mesenchymal Stem Cell Preparation

[0056] 1. Obtaining the fetal umbilical cord

[0057] The isolated umbilical cords of full-term newborns without congenital diseases were obtained; the mothers had no infectious diseases such as hepatitis, syphilis, and AIDS, and the mothers and their families gave informed consent to the use of the umbilical cords in the experimental research.

[0058] 2. Obtaining mesenchymal cells from the Wharton section of the umbilical cord

[0059] 1. In the aseptic laboratory bench, the umbilical cord is repeatedly rinsed with saline to remove residual blood. Cut the umbilical cord into small pieces of 2-3cm with sterile surgical instruments, cut the umbilical cord longitudinally, remove the umbilical artery, umbilical vein and amniotic membrane, take the Wharton area, and cut it into 0.5-1mm 3 Little pieces left and right.

[0060] 2. Obtain primary umbilical cord mesenchymal cells b...

Embodiment 2

[0072] Embodiment 2, identification of P3 cell preparation

[0073] The test product is the P3 cell preparation prepared in Example 1.

[0074] Use flow cytometry to detect the expression of CD29, CD44, CD90, CD105, CD126, CD31, CD45, CD34 and HLA-DR in the test product. The specific steps are: after the cells are incubated with the corresponding antibodies, the excess antibodies are washed away , resuspend the cells with PBS buffer, and use the LSR Fortessa instrument of BD Company to detect the positive rate of each index.

[0075] For the results of markers of mesenchymal stem cells (CD29, CD44, CD90, CD105 and CD126), see figure 1 . For the results of hematopoietic stem cell and endothelial cell markers (CD31, CD45 and CD34), see figure 2 . For the results of transplant rejection-related markers (HLA-DR), see image 3 . The results show that the test product highly expresses markers of mesenchymal stem cells (both positive rates are above 95%), lowly expresses marke...

Embodiment 3

[0076] Embodiment 3, the therapeutic effect of P3 cell preparation on allergic rhinitis

[0077] Antigen adjuvant suspension: ovalbumin 1mg / ml, aluminum hydroxide 2mg / ml, and the balance is normal saline.

[0078] Egg protein solution: 0.1 mg / ml egg protein, and the balance is normal saline.

[0079] 1. Model preparation and administration

[0080] Allergic rhinitis model induced by sensitization of rats with egg protein and aluminum hydroxide gel.

[0081] SD rats, half male and half male, weighing about 250g, were first adapted to feeding for a week (clean animal breeding room, free intake of water), and then grouped as follows (12 rats in each group):

[0082] Cell therapy group: on the first day of the test, inject the antigen adjuvant suspension (one point on the plantar of each hindlimb, three points in the abdominal cavity, a total of 5 points, each point injecting 0.2ml); on the seventh day of the test, inject the antigen adjuvant Suspension (one point on the planta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a cell preparation capable of treating allergic rhinitis. The invention first protects application of mesenchyma stem cells in preparation of drugs used for treating allergic rhinitis. The invention further protects a preparation method of a cell preparation. The preparation method of the cell preparation comprises the following step of preparing umbilical cord mesenchymalstem cells by using a Wharton-area tissue block of the umbilical cord as a raw material, thereby obtaining the cell preparation; and a low-serum medium is adopted during the preparation process. The invention still further protects application of the cell preparation in preparation of drugs used for treating allergic rhinitis. The cell preparation provided by the invention is suitable for cell therapy of allergic rhinitis. The cell preparation is of great application values to treatment of allergic rhinitis.

Description

technical field [0001] The invention relates to a cell preparation for treating allergic rhinitis, which is a human umbilical cord Wharton interval mesenchymal stem cell preparation, and also relates to its preparation method and application. Background technique [0002] Allergic rhinitis (AR), also known as allergic rhinitis, is a common otolaryngology disease and a common respiratory allergic disease. The disease is an allergic disease occurring in the nasal mucosa, characterized by nasal itching, sneezing, rhinorrhea, and swelling of the nasal mucosa. The prevalence of allergic rhinitis is 10%-40%, among which pollen allergy is more common in Europe and North America, and perennial allergic rhinitis is more common in Asia. Although allergic rhinitis is not fatal, the patient's nose and general discomfort are obvious, which affects the patient's study and work. If not treated correctly, about 30% of patients will develop bronchial asthma, or even pulmonary heart disease...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/51A61P11/02A61P37/08C12N5/0775
CPCA61K35/51A61P11/02A61P37/08C12N5/0665C12N2509/00
Inventor 常智杰付艳霞王银银任芳丽
Owner TSINGHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com